Evidence map›Paper›PMID 33833397›Full record

ArticleOncogene2021

CCL8 mediates crosstalk between endothelial colony forming cells and triple-negative breast cancer cells through IL-8, aggravating invasion and tumorigenicity.

Eun-Sook Kim, Su-Min Nam, Hye Kyung Song, Seungeun Lee, Kyoungmee Kim, Hyun Kyung Lim, Hyunsook Lee, Kyu-Tae Kang, Yeo-Jung Kwon, Young-Jin Chun and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. The pleiotropic roles of adipocyte secretome in remodeling breast cancer.Journal of experimental & clinical cancer research : CR · 2022
    Review
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Eun-Sook KimDuksung Innovative Drug Center, College of Pharmacy, Duksung Women's University, Seoul, Korea.
Su-Min NamDuksung Innovative Drug Center, College of Pharmacy, Duksung Women's University, Seoul, Korea.
Hye Kyung SongCollege of Chemistry, Duksung Women's University, Seoul, Korea.
Seungeun LeeDuksung Innovative Drug Center, College of Pharmacy, Duksung Women's University, Seoul, Korea.
Kyoungmee KimDuksung Innovative Drug Center, College of Pharmacy, Duksung Women's University, Seoul, Korea.
Hyun Kyung LimDuksung Innovative Drug Center, College of Pharmacy, Duksung Women's University, Seoul, Korea.
Hyunsook LeeDuksung Innovative Drug Center, College of Pharmacy, Duksung Women's University, Seoul, Korea.
Kyu-Tae KangDuksung Innovative Drug Center, College of Pharmacy, Duksung Women's University, Seoul, Korea.
Yeo-Jung KwonCollege of Pharmacy, Chung-Ang University, Seoul, Korea.
Young-Jin ChunCollege of Pharmacy, Chung-Ang University, Seoul, Korea.
So Yeon ParkDepartment of Pathology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.ORCID http://orcid.org/0000-0002-0299-7268
Joohee JungDuksung Innovative Drug Center, College of Pharmacy, Duksung Women's University, Seoul, Korea. joohee@duksung.ac.kr.ORCID http://orcid.org/0000-0001-9124-9052
Aree MoonDuksung Innovative Drug Center, College of Pharmacy, Duksung Women's University, Seoul, Korea. armoon@duksung.ac.kr.ORCID http://orcid.org/0000-0001-5044-8813
Duksung Women's University · KRChung-Ang University · KRSeoul National University Bundang Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with a poor prognosis for which no effective therapeutic measures are currently available. The present study aimed to investigate whether interactions with endothelial colony-forming cells (ECFCs) promote aggressive progression of TNBC cells. Herein, using an indirect co-culture system, we showed that co-culture increased the invasive and migratory phenotypes of both MDA-MB-231 TNBC cells and ECFCs. Through a cytokine antibody array and RT-PCR analysis, we revealed that co-culture markedly induced secretion of the chemokine C-C motif ligand (CCL)8 from ECFCs and that of interleukin (IL)-8 from MDA-MB-231 cells. CCL8 was crucial for ECFC-induced IL-8 secretion and invasion of MDA-MB-231 cells as well as for MDA-MB-231-enhanced MMP-2 secretion and angiogenesis of ECFCs. We suggest c-Jun as a transcription factor for CCL8-induced IL-8 expression in MDA-MB-231 cells. IL-8 was important for co-culture-induced CCL8 and MMP-2 upregulation and invasion of ECFCs. Notably, our findings reveal a positive feedback loop between CCL8 and IL-8, which contributes to the aggressive phenotypes of both ECFC and TNBC cells. Using an MDA-MB-231 cell-based xenograft model, we show that tumor growth and metastasis are increased by co-injected ECFCs in vivo. Increased expression of IL-8 was observed in tissues with bone metastases in mice injected with conditioned media from co-cultured cells. High IL-8 levels are correlated with poor recurrence-free survival in TNBC patients. Together, these results suggest that CCL8 and IL-8 mediate the crosstalk between ECFCs and TNBC, leading to aggravation of tumorigenicity in TNBC.

Indexed as

Chemokine CCL8Endothelial CellsInterleukin-8Neoplasm InvasivenessTriple Negative Breast NeoplasmsAnimalsCarcinogenesisCell CommunicationCell Line, TumorCell MovementCoculture TechniquesFemaleHumansMiceCCL8 protein, humanChemokine CCL8CXCL8 protein, humanInterleukin-8

Identifiers

PMID33833397
OpenAlexW3146660225

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.